Answers are grounded in this paper and cite their sources.
The receptor for advanced glycation end products (RAGE) transduces the impact of the products of nonenzymatic glycation and oxidation of proteins, the advanced glycation end products, proinflammatory ligands S100/calgranulins and high mobility group box 1. The ligand families of RAGE accumulate in the vasculature in diabetes and are enriched in atherosclerotic lesions, both in human and animal models. Experimentation in animal models of both Type 1 and 2 diabetes reveals that antagonism of the ligand–RAGE axis suppresses the development and progression of vascular and inflammatory cell perturbation in the diabetic milieu; key processes linked to acceleration of atherosclerosis and exaggerated neointimal expansion consequent to arterial injury. We propose that blockade of RAGE may represent an effective target for therapeutic intervention in diabetes and its cardiovascular complications.
No takes yet. Share an insight, caveat, or question.
Ramasamy et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: